{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:42:42Z","timestamp":1790005362794,"version":"4.0.1"},"reference-count":95,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>Despite improvements in hypertension awareness and treatment, 30%\u201360% of hypertensive patients do not achieve BP targets and subsequently remain at risk for target organ damage. This therapeutic gap is particularly important to nephrologists, who frequently encounter treatment-resistant hypertension in patients with CKD. Data are limited on how best to treat patients with CKD and resistant hypertension, because patients with CKD have historically been excluded from hypertension treatment trials. First, we propose a consistent definition of resistant hypertension as BP levels confirmed by both in-office and out-of-office measurements that exceed appropriate targets while the patient is receiving treatment with at least three antihypertensive medications, including a diuretic, at dosages optimized to provide maximum benefit in the absence of intolerable side effects. Second, we recommend that each patient undergo a standardized, stepwise evaluation to assess adherence to dietary and lifestyle modifications and antihypertensive medications to identify and reduce barriers and discontinue use of substances that may exacerbate hypertension. Patients in whom there is high clinical suspicion should be evaluated for potential secondary causes of hypertension. Evidence-based management of resistant hypertension is discussed with special considerations of the differences in approach to patients with and without CKD, including the specific roles of diuretics and mineralocorticoid receptor antagonists and the current place of emerging therapies, such as renal denervation and baroreceptor stimulation. We endorse use of such a systematic approach to improve recognition and care for this vulnerable patient group that is at high risk for future kidney and cardiovascular events.<\/jats:p>","DOI":"10.2215\/cjn.06180616","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T21:20:42Z","timestamp":1480368042000},"page":"524-535","source":"Crossref","is-referenced-by-count":52,"title":["Recognition and Management of Resistant Hypertension"],"prefix":"10.2215","volume":"12","author":[{"given":"Branko","family":"Braam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Taler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Fillaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrain","family":"Reisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad G.","family":"Saklayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Susan","family":"Hedayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.","volume":"124","author":"Egan","year":"2011","journal-title":"Circulation"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1503\/cmaj.101767","article-title":"Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades.","volume":"183","author":"McAlister","year":"2011","journal-title":"CMAJ"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: Diagnosis, evaluation, and treatment:A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/HYPERTENSIONAHA.114.03718","article-title":"Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel.","volume":"64","author":"Weitzman","year":"2014","journal-title":"Hypertension"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"II65","DOI":"10.1161\/01.HYP.11.3_Pt_2.II65","article-title":"Resistant hypertension. Introduction and definitions.","volume":"11","author":"Gifford","year":"1988","journal-title":"Hypertension"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","article-title":"2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH\/ESC Task Force for the Management of Arterial Hypertension.","volume":"31","year":"2013","journal-title":"J Hypertens"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/eurheartj\/ehs368","article-title":"Resistant hypertension: A frequent and ominous finding among hypertensive patients with atherothrombosis.","volume":"34","author":"Kumbhani","year":"2013","journal-title":"Eur Heart J"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).","volume":"4","author":"Cushman","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jacc.2012.12.061","article-title":"Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients.","volume":"61","author":"De Nicola","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/HJH.0b013e32834a8a42","article-title":"Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): A risk score to identify those at high-risk.","volume":"29","author":"Gupta","year":"2011","journal-title":"J Hypertens"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"64","author":"Muntner","year":"2014","journal-title":"Hypertension"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","article-title":"Prevalence of resistant hypertension in the United States, 2003-2008.","volume":"57","author":"Persell","year":"2011","journal-title":"Hypertension"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/HJH.0000000000000051","article-title":"Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension.","volume":"32","author":"Smith","year":"2014","journal-title":"J Hypertens"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.","volume":"57","author":"de la Sierra","year":"2011","journal-title":"Hypertension"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.","volume":"62","author":"Egan","year":"2013","journal-title":"Hypertension"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: Report from the Chronic Renal Insufficiency Cohort Study.","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.115.05694","article-title":"Prevalence of apparent therapy-resistant hypertension and its effect on outcome in patients with chronic kidney disease.","volume":"66","author":"de Beus","year":"2015","journal-title":"Hypertension"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients.","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1524-6175.2005.04377.x","article-title":"Recommendations for blood pressure measurement in humans: An AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee.","volume":"7","author":"Pickering","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1097\/HJH.0b013e32833b49fe","article-title":"Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations.","volume":"28","author":"Fan","year":"2010","journal-title":"J Hypertens"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.ki.5000177","article-title":"Hypertension in renal parenchymal disease: Why is it so resistant to treatment?","volume":"69","author":"Campese","year":"2006","journal-title":"Kidney Int"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa013410","article-title":"Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes.","volume":"347","author":"Lurbe","year":"2002","journal-title":"N Engl J Med"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.166.8.846","article-title":"Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate.","volume":"166","author":"Davidson","year":"2006","journal-title":"Arch Intern Med"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.TP.0000435704.55805.f9","article-title":"Home blood pressure monitoring in heart transplant recipients: Comparison with ambulatory blood pressure monitoring.","volume":"97","author":"Ambrosi","year":"2014","journal-title":"Transplantation"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jash.2014.06.005","article-title":"Detection, evaluation, and treatment of severe and resistant hypertension: Proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013.","volume":"8","author":"White","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis.","volume":"31","author":"Jung","year":"2013","journal-title":"J Hypertens"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis.","volume":"100","author":"Tomaszewski","year":"2014","journal-title":"Heart"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000321688","article-title":"Adherence to antihypertensive agents and blood pressure control in chronic kidney disease.","volume":"32","author":"Schmitt","year":"2010","journal-title":"Am J Nephrol"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00004872-200102000-00022","article-title":"Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions.","volume":"19","author":"Burnier","year":"2001","journal-title":"J Hypertens"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication.","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/jhh.2015.38","article-title":"Non-adherence to antihypertensive medication is very common among resistant hypertensives: Results of a directly observed therapy clinic.","volume":"30","author":"Hameed","year":"2016","journal-title":"J Hum Hypertens"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/HYPERTENSIONAHA.110.152918","article-title":"Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: A systematic review and meta-analysis.","volume":"56","author":"Trinquart","year":"2010","journal-title":"Hypertension"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00063198-200111000-00003","article-title":"Prediction formulae for sleep-disordered breathing.","volume":"7","author":"Harding","year":"2001","journal-title":"Curr Opin Pulm Med"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/HJH.0b013e328351d08a","article-title":"Resistant hypertension and obstructive sleep apnea in the setting of kidney disease.","volume":"30","author":"Abdel-Kader","year":"2012","journal-title":"J Hypertens"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1378\/chest.13-0085","article-title":"Effects of OSA treatment on BP in patients with resistant hypertension: A randomized trial.","volume":"144","author":"Pedrosa","year":"2013","journal-title":"Chest"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1378\/chest.13-1115","article-title":"Effect of CPAP on blood pressure in patients with OSA\/hypopnea a systematic review and meta-analysis.","volume":"145","author":"Fava","year":"2014","journal-title":"Chest"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa1306187","article-title":"CPAP, weight loss, or both for obstructive sleep apnea.","volume":"370","author":"Chirinos","year":"2014","journal-title":"N Engl J Med"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjhyper.2005.01.002","article-title":"Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.","volume":"18","author":"Nishizaka","year":"2005","journal-title":"Am J Hypertens"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","article-title":"The double challenge of resistant hypertension and chronic kidney disease.","volume":"386","author":"Rossignol","year":"2015","journal-title":"Lancet"},{"key":"B44-20230813","first-page":"2083","article-title":"Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial.","volume":"289","author":"Appel","year":"2003","journal-title":"JAMA"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","article-title":"A clinical trial of the effects of dietary patterns on blood pressure.","volume":"336","author":"Appel","year":"1997","journal-title":"N Engl J Med"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.jhh.1001775","article-title":"Dose-response of sodium excretion and blood pressure change among overweight, nonhypertensive adults in a 3-year dietary intervention study.","volume":"19","author":"Cook","year":"2005","journal-title":"J Hum Hypertens"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2011.46","article-title":"Non-pharmacological aspects of blood pressure management: What are the data?","volume":"79","author":"Hedayati","year":"2011","journal-title":"Kidney Int"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1161\/01.HYP.0000037217.96002.8E","article-title":"Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT).","volume":"40","author":"Miller","year":"2002","journal-title":"Hypertension"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archinte.1997.00440270105009","article-title":"Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The trials of hypertension prevention, phase II.","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"key":"B50-20230813","first-page":"CD008274","article-title":"Long-term effects of weight-reducing diets in people with hypertension.","volume":"3","author":"Semlitsch","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B51-20230813","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1161\/CIR.0b013e3182149099","article-title":"Bariatric surgery and cardiovascular risk factors: A scientific statement from the American Heart Association.","volume":"123","author":"Poirier","year":"2011","journal-title":"Circulation"},{"key":"B52-20230813","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/oby.2001.20","article-title":"Blood pressure and pulse pressure during long-term weight loss in the obese: The Swedish Obese Subjects (SOS) Intervention Study.","volume":"9","author":"Sj\u00f6str\u00f6m","year":"2001","journal-title":"Obes Res"},{"key":"B53-20230813","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.HYP.36.1.20","article-title":"Differentiated long-term effects of intentional weight loss on diabetes and hypertension.","volume":"36","author":"Sj\u00f6str\u00f6m","year":"2000","journal-title":"Hypertension"},{"key":"B54-20230813","first-page":"2416","article-title":"Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity.","volume":"310","author":"Courcoulas","year":"2013","journal-title":"JAMA"},{"key":"B55-20230813","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/HJH.0000000000000526","article-title":"Roux-en-Y gastric bypass alleviates hypertension and is associated with an increase in mid-regional pro-atrial natriuretic peptide in morbid obese patients.","volume":"33","author":"Bonfils","year":"2015","journal-title":"J Hypertens"},{"key":"B56-20230813","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1001\/archinte.168.21.2355","article-title":"A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: Study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN).","volume":"168","author":"McLean","year":"2008","journal-title":"Arch Intern Med"},{"key":"B57-20230813","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.111.188409","article-title":"Effect of home blood pressure telemonitoring with self-care support on uncontrolled systolic hypertension in diabetics.","volume":"60","author":"Logan","year":"2012","journal-title":"Hypertension"},{"key":"B58-20230813","doi-asserted-by":"crossref","first-page":"f3030","DOI":"10.1136\/bmj.f3030","article-title":"Telemonitoring based service redesign for the management of uncontrolled hypertension: Multicentre randomised controlled trial.","volume":"346","author":"McKinstry","year":"2013","journal-title":"BMJ"},{"key":"B60-20230813","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1161\/HYP.0b013e318293645f","article-title":"Beyond medications and diet: Alternative approaches to lowering blood pressure: A scientific statement from the american heart association.","volume":"61","author":"Brook","year":"2013","journal-title":"Hypertension"},{"key":"B61-20230813","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrneph.2009.191","article-title":"Prehypertension: Epidemiology, consequences and treatment.","volume":"6","author":"Pimenta","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B62-20230813","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1097\/HJH.0b013e32835476e1","article-title":"Getting the message across: Opportunities and obstacles in effective communication in hypertension care.","volume":"30","author":"Jolles","year":"2012","journal-title":"J Hypertens"},{"key":"B63-20230813","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8).","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"B64-20230813","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1046\/j.1523-1755.2003.00273.x","article-title":"Role of excess volume in the pathophysiology of hypertension in chronic kidney disease.","volume":"64","author":"Vasavada","year":"2003","journal-title":"Kidney Int"},{"key":"B65-20230813","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med"},{"key":"B66-20230813","doi-asserted-by":"crossref","first-page":"F958","DOI":"10.1152\/ajprenal.00476.2015","article-title":"Everything we always wanted to know about furosemide but were afraid to ask.","volume":"310","author":"Huang","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"B67-20230813","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jash.2010.10.001","article-title":"The effect of low-dose spironolactone on resistant hypertension.","volume":"4","author":"Engbaek","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"B68-20230813","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/MD.0000000000000162","article-title":"Effect of spironolactone in resistant arterial hypertension: A randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT).","volume":"93","author":"V\u00e1clav\u00edk","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"B69-20230813","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial.","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"B70-20230813","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/j.ackd.2014.12.001","article-title":"Management of hypertension in CKD: Beyond the guidelines.","volume":"22","author":"Judd","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"B71-20230813","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ndt\/gfm542","article-title":"Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease.","volume":"23","author":"Essig","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B72-20230813","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ki.2013.336","article-title":"Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease.","volume":"85","author":"Hung","year":"2014","journal-title":"Kidney Int"},{"issue":"Suppl 4","key":"B73-20230813","doi-asserted-by":"crossref","first-page":"iv31","DOI":"10.1093\/ndt\/gfs420","article-title":"Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD).","volume":"27","author":"Verdalles","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B74-20230813","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/01.HYP.0000209642.11448.e0","article-title":"Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects.","volume":"47","author":"Smith","year":"2006","journal-title":"Hypertension"},{"key":"B75-20230813","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","article-title":"Resistant hypertension: Comparing hemodynamic management to specialist care.","volume":"39","author":"Taler","year":"2002","journal-title":"Hypertension"},{"key":"B76-20230813","doi-asserted-by":"crossref","first-page":"242","DOI":"10.12659\/MSM.883870","article-title":"A \u201cpatient-tailored\u201d treatment of hypertension with use of impedance cardiography: A randomized, prospective and controlled trial.","volume":"19","author":"Krzesi\u0144ski","year":"2013","journal-title":"Med Sci Monit"},{"key":"B77-20230813","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1139\/apnm-2013-0322","article-title":"Developing a Web-based dietary sodium screening tool for personalized assessment and feedback.","volume":"39","author":"Arcand","year":"2014","journal-title":"Appl Physiol Nutr Metab"},{"key":"B79-20230813","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa0905368","article-title":"Revascularization versus medical therapy for renal-artery stenosis.","volume":"361","author":"Wheatley","year":"2009","journal-title":"N Engl J Med"},{"key":"B80-20230813","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1310753","article-title":"Stenting and medical therapy for atherosclerotic renal-artery stenosis.","volume":"370","author":"Cooper","year":"2014","journal-title":"N Engl J Med"},{"key":"B81-20230813","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1161\/CIRCULATIONAHA.106.174526","article-title":"ACC\/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery\/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC\/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.","volume":"113","author":"Hirsch","year":"2006","journal-title":"Circulation"},{"key":"B82-20230813","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease.","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B83-20230813","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","article-title":"Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial.","volume":"54","author":"Pimenta","year":"2009","journal-title":"Hypertension"},{"key":"B84-20230813","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archinte.1970.00310010071005","article-title":"The short-term effect of furosemide on electrolyte and water excretion in patients with severe renal disease.","volume":"125","author":"Gregory","year":"1970","journal-title":"Arch Intern Med"},{"key":"B85-20230813","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/HYPERTENSIONAHA.111.190637","article-title":"Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate.","volume":"59","author":"Peterzan","year":"2012","journal-title":"Hypertension"},{"key":"B86-20230813","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/HYPERTENSIONAHA.112.191106","article-title":"Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: Systematic review and network meta-analyses.","volume":"59","author":"Roush","year":"2012","journal-title":"Hypertension"},{"key":"B87-20230813","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.114.05122","article-title":"Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: Systematic review and meta-analysis.","volume":"65","author":"Olde Engberink","year":"2015","journal-title":"Hypertension"},{"key":"B88-20230813","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","article-title":"Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.","volume":"47","author":"Ernst","year":"2006","journal-title":"Hypertension"},{"key":"B89-20230813","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11906-014-0525-x","article-title":"Thiazide diuretics in chronic kidney disease.","volume":"17","author":"Sinha","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"B90-20230813","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/HYPERTENSIONAHA.108.119883","article-title":"Assessment of sympathetic cardiovascular drive in human hypertension: Achievements and perspectives.","volume":"54","author":"Grassi","year":"2009","journal-title":"Hypertension"},{"key":"B91-20230813","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJM194311252292201","article-title":"Blood-pressure determinations in patients with essential hypertension. III. Evaluation of sympathectomy over a three-year to five-year period.","volume":"229","author":"Ayman","year":"1943","journal-title":"N Engl J Med"},{"key":"B92-20230813","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study.","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"B93-20230813","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jacc.2012.05.036","article-title":"A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension.","volume":"60","author":"Pokushalov","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B94-20230813","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension.","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"B95-20230813","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial.","volume":"385","author":"Azizi","year":"2015","journal-title":"Lancet"},{"key":"B96-20230813","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jcin.2016.04.013","article-title":"Externally delivered focused ultrasound for renal denervation.","volume":"9","author":"Neuzil","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"B97-20230813","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1161\/CIRCULATIONAHA.110.991869","article-title":"Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study.","volume":"123","author":"Mahfoud","year":"2011","journal-title":"Circulation"},{"key":"B98-20230813","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijcard.2014.03.017","article-title":"Improvement of albuminuria after renal denervation.","volume":"173","author":"Ott","year":"2014","journal-title":"Int J Cardiol"},{"key":"B99-20230813","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1161\/HYPERTENSIONAHA.111.173799","article-title":"Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea.","volume":"58","author":"Witkowski","year":"2011","journal-title":"Hypertension"},{"key":"B100-20230813","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fphys.2014.00311","article-title":"What is the true incidence of renal artery stenosis after sympathetic denervation?","volume":"5","author":"Wang","year":"2014","journal-title":"Front Physiol"},{"key":"B101-20230813","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial.","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201703000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:36:25Z","timestamp":1786368985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201703000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.06180616","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]}}}